Morgan Stanley
SIOX

Morgan Stanley’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Morgan Stanley’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,512,380
Closed -$658K – 7901
2022
Q4 		$658K Buy
1,512,380
+1,500,000
+12,116% +$487K ﹤0.01% 5095
2022
Q3 		$4K Sell
12,380
-1
-0% – ﹤0.01% 7354
2022
Q2 		$4K Sell
12,381
-4,873
-28% -$2.02K ﹤0.01% 7485
2022
Q1 		$12K Sell
17,254
-842
-5% -$715 ﹤0.01% 7363
2021
Q4 		$24K Sell
18,096
-50,287
-74% -$89.2K ﹤0.01% 7151
2021
Q3 		$149K Buy
68,383
+39,471
+137% +$85.8K ﹤0.01% 6149
2021
Q2 		$79K Sell
28,912
-28,406
-50% -$70.6K ﹤0.01% 6457
2021
Q1 		$150K Sell
57,318
-296,568
-84% -$839K ﹤0.01% 5812
2020
Q4 		$983K Buy
353,886
+349,556
+8,073% +$1.02M ﹤0.01% 4681
2020
Q3 		$20K Buy
4,330
+1,330
+44% +$4.39K ﹤0.01% 6076
2020
Q2 		$8K Buy
3,000
+2,151
+253% +$6.9K ﹤0.01% 6227
2020
Q1 		$2K Sell
849
-1,842
-68% -$6.65K ﹤0.01% 6422
2019
Q4 		$13K Sell
2,691
-2,083
-44% -$11.6K ﹤0.01% 6206
2019
Q3 		$30K Buy
4,774
+4,425
+1,268% +$30.5K ﹤0.01% 5899
2019
Q2 		$2K Sell
349
-27,038
-99% -$206K ﹤0.01% 6489
2019
Q1 		$291K Buy
27,387
+23,874
+680% +$238K ﹤0.01% 4864
2018
Q4 		$29K Buy
3,513
+722
+26% +$10.4K ﹤0.01% 5939
2018
Q3 		$54K Sell
2,791
-37,465
-93% -$682K ﹤0.01% 5863
2018
Q2 		$727K Buy
40,256
+30,843
+328% +$455K ﹤0.01% 4841
2018
Q1 		$100K Sell
9,413
-115,353
-92% -$1.85M ﹤0.01% 5708
2017
Q4 		$5.26M Buy
124,766
+108,782
+681% +$4.88M ﹤0.01% 3063
2017
Q3 		$879K Buy
15,984
+4,222
+36% +$712K ﹤0.01% 4515
2017
Q2 		$2.18M Buy
11,762
+2,840
+32% +$498K ﹤0.01% 3720
2017
Q1 		$1.07M Sell
8,922
-4,929
-36% -$517K ﹤0.01% 4338
2016
Q4 		$1.38M Buy
13,851
+8,347
+152% +$879K ﹤0.01% 4219
2016
Q3 		$616K Buy
5,504
+4,459
+427% +$535K ﹤0.01% 4397
2016
Q2 		$107K Sell
1,045
-739
-41% -$73.9K ﹤0.01% 5214
2016
Q1 		$163K Sell
1,784
-2,070
-54% -$221K ﹤0.01% 5090
2015
Q4 		$556K Buy
3,854
+3,344
+656% +$435K ﹤0.01% 4473
2015
Q3 		$53K Sell
510
-21,898
-98% -$2.57M ﹤0.01% 5704
2015
Q2 		$3.65M Buy
+22,408
New +$3.8M ﹤0.01% 3074

Other funds holding SIOX

JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
CIA
Cladis Investment Advisory Billings, Montana $182M AUM 33.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Morgan Stanley's SIOX Position: Q1 2023 in Review

Morgan Stanley sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q1 2023, closing a stake of 1,512,380 shares — an estimated $658K sold.

Morgan Stanley first reported a position in SIOX in Q2 2015 and held it in 31 quarters. The position peaked at $5.26M in Q4 2017. 4 funds tracked by Wall St. Rank hold SIOX as of Q1 2023.

  • Morgan Stanley reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • Morgan Stanley sold 1,512,380 Sio Gene Therapies Inc. Common Stock shares in Q1 2023, an estimated $658K.
  • Morgan Stanley first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2015 and held it in 31 quarters.
  • Morgan Stanley's Sio Gene Therapies Inc. Common Stock position peaked at $5.26M in Q4 2017.
  • 4 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q1 2023.

Based on Morgan Stanley's 13F filing for Q1 2023, filed 15 May 2023.